Full body MRI company lands FDA clearance for body composition report and adds brain health and blood-based biomarker assessments.
Whole-body MRI technology company Prenuvo has revealed that it raised $120 million in 2024 as part of a Series B funding round to advance its position in preventative healthcare. The company also announced it has secured FDA clearance for its Prenuvo Body Composition report, which will be combine with other new innovations as part of a new “Enhanced” offering.
Prenuvo’s technology allows for a full-body MRI scan in under an hour, capturing over one billion data points and generating significantly more clinical-grade images than conventional MRIs. The company’s FDA-cleared body composition report leverages AI to provide a comprehensive analysis of visceral fat, subcutaneous fat, liver fat, muscle volumes and the volume of key abdominal organs. Prenuvo also introduced additional advancements to its health screening capabilities, including a new brain health scan that provides critical insights into brain function, cognitive health and early markers of neurodegenerative diseases.
Complementing its imaging technology, the company has also developed a functional and conventional blood biomarker assessment. This custom panel of blood tests delivers metabolic, cardiovascular, hormonal and immune health insights, working in tandem with imaging to offer a more complete picture of a patient’s well-being.
The new innovations will launch immediately in Prenuvo’s Silicon Valley, Los Angeles and New York locations as part of a bundled offering called Prenuvo Enhanced, with further rollout planned for additional locations in the spring.
“We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge,” said Prenuvo CEO Andrew Lacy. “This isn’t just about healthcare; it’s about reimagining how we approach health, using cutting-edge technology and world-class expertise to prevent disease and help people live longer, healthier lives.”
Last year, Prenuvo launched a clinical research study that will follow 100,000 participants over a decade to identify new disease biomarkers and assess the outcomes of whole-body MRI screening. The company also recently presented a study demonstrating how its technology was able to clarify the link between Type 2 diabetes and brain volume loss.
The Series B round was co-led by Forerunner Ventures, Left Lane Capital and Felicis, and is intended to fuel Prenuvo’s expansion into new modalities and international markets. The company currently operates preventive screening clinics in 16 US cities and plans to establish 15 additional clinics, including locations in the UK, Europe and Australia, marking its first move beyond North America.
“With only 2.5% of healthcare spending focused on preventative medicine, the US system waits for people to become sick before intervening,” said Forerunner’s Brian O’Malley. “Consumers have grown tired of this and are responding with their own wallets. Prenuvo is the preeminent solution for a comprehensive understanding of one’s health, giving today’s patients unprecedented levels of knowledge to not just understand, but proactively intervene in the challenges that arise as we all age. Longevity is the new luxury and Prenuvo is democratizing access so that more can benefit from this.”
